The European patent for REMaST, Hemera’s proprietary technology for nervous tissue regeneration, has been published in Issue 24/25 of the European Patent Office (EPO) Bulletin on June 11, 2025
https://www.epo.org/bulletin/downloads/2025/bulletin2524.pdf.
The patent protects the cell product developed by Hemera, the method for obtaining regenerative macrophages, and their use in tissue repair and regeneration processes—a discovery resulting from years of research, study, and experimentation.
This European recognition marks a major milestone in the scientific and commercial development of our therapy, strengthening Hemera’s ability to attract strategic partnerships and investment, and opening new opportunities for the international clinical application of REMaST.